Robotic Surgery in Patients With Locally Advanced Cervical Cancer After Neoadjuvant Chemotherapy: Survival Outcomes.

AIM: To evaluate the survival outcomes of consecutive patients with locally advanced cervical cancer (LACC) who underwent comprehensive robotic surgery after neoadjuvant chemotherapy (NACT). MATERIALS AND METHODS: Since 2009, patients with LACC (FIGO [International Federation of Gynecology and Obstetrics] stages IB2-IIB) were submitted to robotic surgical staging after 3 cycles of NACT. Clinical objective tumor response was assessed according to the Response Evaluation Criteria in Solid Tumors, whereas pathologic responses were defined according to the criteria of the European study SNAP01. Univariable and multivariable analyses were performed to assess potential clinicopathologic prognostic factors affecting progression-free survival and overall survival (OS). RESULTS: During the study period, 32 patients meeting the inclusion criteria were managed. The median (range) age and body mass index were 47.3 (8.6-75.5) years and 22.7 (17.5-37.1) kg/m(2), respectively. Overall, 28.0 (range, 12-58) lymph nodes were retrieved. According to the final pathologic examination, 6 (18.8%) women had positive pelvic lymph nodes, whereas 16 (50.0%) patients achieved an optimal pathological response. After a median follow-up of 36.3 (range, 5.2-71.1) months, 6 (18.8%) patients had a recurrence and subsequently died of disease.Positive nodal status was the only independent predictor of both progression-free survival (12.5 [2.3-69.1]; P < 0.0001) and OS (12.0 [2.0-60.4]; P < 0.0001) at multivariable analysis. CONCLUSIONS: Nodal status represents the strongest predictor of survival in women with LACC. Similarly, NACT including 3 agents (TIP [paclitaxel 175 mg/m(2) + ifosfamide 5 g/m(2) + cisplatin 75 mg/m(2)] and TEP [paclitaxel 175 mg/m(2) + epirubicin 80 mg/m(2) + cisplatin 75 mg/m(2)] regimens) warranted better OS than those achieved by other schedules.

Survival outcomes after surgical management of endometrial cancer: Analysis after the first 10-year experience of robotic surgery in a single center.

OBJECTIVES: To report the 5-year survival rates of patients undergone surgery for endometrial cancer, within a 10-year study. METHODS: Single institution series with a minimum 2-year follow-up. The 5-year survival outcomes of patients managed by robotics, laparoscopy and open surgery during the same period were compared. Multivariable analyses were performed to identify prognostic factors. RESULTS: Three hundred and sixty-three consecutive patients were analysed. Open surgery showed a higher rate of abdominal recurrences (17.2% vs. 3.3%; p < 0.001); no differences were recorded in terms of vaginal, nodal or distant recurrences between open and minimally invasive surgery. At multivariable analyses, type II histology, peritoneal cytology and lympho-vascular space invasion were independent predictors for survival. Based on each FIGO (The International Federation of Gynecology and Obstetrics) stage, no differences were found in terms of 5-year disease-free survival and overall survival between the approaches. CONCLUSIONS: The surgical route does not affect the 5-year survival in patients with endometrial cancer. Both robotics and laparoscopy are confirmed as viable options.

Survival outcomes of robotic radical hysterectomy for early stage cervical cancer: A 9-year study.

BACKGROUND: Recently, the results of a RCT have raised concerns on the management of cervical cancer through a minimally invasive approach. This study reports on the outcomes of patients with early stage cervical cancer submitted to robotics. METHODS: Retrospective review of a consecutive series of patients with an early cervical cancer treated with robotics at a single Institution over a 9-year period. RESULTS: A total of 91 women were managed; 39 (41.1%) had cervical adenocarcinoma. One (1.1%) conversion to laparotomy and one (1.1%) intraoperative complication occurred. Five (5.5%) patients experienced postoperative (>G2) complications; 24 (26.4%) patients required further adjuvant therapies. After a median follow-up of 40.7 (3.8-96.6) months, the DFS and OS were 90.4 (95%CI 85.3-95.6)% and 94.5 (95%CI 91.8-97.2)%, respectively. CONCLUSIONS: According to the available literature, the survival outcomes of this series of RRH for ECC are not inferior to what recorded in the past by an open approach.